Author

D. A. Harki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Microbiology· 2 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Research Focus:protein structure prediction· 1 Assay:structural biology· 1

Frequent Co-Authors

C. E. Cameron· 2 shared H. Aihara· 2 shared J. J. Arnold· 2 shared J. Tang· 2 shared K. Shi· 2 shared N. M. Levinson· 2 shared O. Demir· 2 shared R. E. Amaro· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

C. E. Cameron

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Rapid resistance profiling of SARS-CoV-2 protease inhibitors

S. A. Moghadasi, R. Biswas, D. A. Harki, R. Harris

The paper compares resistance profiles of nirmatrelvir, ensitrelvir, and FB2001 against SARS-CoV-2 Mpro variants using a cell-based assay, revealing distinct resistance mechanisms.

bioRxiv · Feb 25, 2023Microbiology

Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease

R. Chinthapatla, M. S. Sotoudegan, T. Anderson, I. M. Moustafa, K. T. Passow, S. A. Kennelly, R. Moorthy, D. Dulin, J. Y. Feng, D. A. Harki, R. Kirchdoerfer, C. E. Cameron, J. J. Arnold

This study investigates how SARS-CoV-2's ExoN enzyme processes RNA and identifies modifications that block its activity, offering potential for new antiviral strategies.

bioRxiv · Aug 11, 2022Biochemistry

Development of allosteric, selective cyclin-dependent kinase 2 (CDK2) inhibitors that are negatively cooperative with cyclin binding and show potential as contraceptive agents

E. B. Faber, J. Tang, E. Roberts, S. Ganeshkumar, L. Sun, N. Wang, D. Rasmussen, A. Majumbar, K. John, A. Yang, H. Khalid, J. E. Hawkinson, N. M. Levinson, E. Schonbrunn, V. Chennathukuzhi, , G. I. Georg

This paper develops high-affinity, structurally confirmed allosteric CDK2 inhibitors that show negative cooperativity with cyclin binding and demonstrate contraceptive potential in mouse testicular explants.

bioRxiv · Jun 30, 2022 · PreprintPharmacology & Toxicology

Targeting N-Myc in Neuroblastoma with Selective Aurora Kinase A Degraders

J. Tang, R. Moorthy, O. Demir, Z. D. Baker, J. A. Naumann, K. F. M. Jones, M. J. Grillo, E. S. Haefner, K. Shi, M. J. Levy, H. Aihara, R. S. Harris, R. E. Amaro, N. M. Levinson, D. A. Harki

This study develops a first-in-class Aurora-A/N-Myc degrader, HLB-0532259, which effectively reduces N-Myc levels and shows tumor reduction in neuroblastoma models.

bioRxiv · Apr 9, 2022Cancer Biology

Induced copy-back RNA synthesis as a novel therapeutic mechanism against RNA viruses

R. Janissen, A. Woodman, K.-M. Lee, I. Moustafa, F. Fitzgerald, P.-N. Huang, L. Kuijpers, A. L. Perkins, D. A. Harki, J. J. Arnold, B. Solano, S.-R. Shih, C. E. Cameron, N. H. Dekker

This study shows that a ribonucleotide analogue induces copy-back RNA synthesis, a new mechanism to combat RNA viruses by promoting defective viral genomes.

bioRxiv · Feb 12, 2020 · PreprintMicrobiology

Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B

K. Shi, O. Demir, M. A. Carpenter, S. Banerjee, D. A. Harki, R. E. Amaro, R. S. Harris, H. Aihara

This study reports structures of APOBEC3B with loop 7 from APOBEC3G, revealing inactive conformations stabilized by small molecules, providing insights for inhibitor design.

bioRxiv · Jan 7, 2019Biochemistry